SEC Form 4 · accession 0001831410-26-000008
Olema Pharmaceuticals, Inc. · OLMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cyrus Harmon
Director
Period of report
Jul 23, 2026
Accepted (ET)
Jul 27, 2026 · 7:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001750284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 23, 2026 | S | 12,500 | $11.579 | D | 715,270 | D | |
| Common StockF2 | Jul 24, 2026 | S | 12,500 | $11.714 | D | 702,770 | D | |
| Common StockF3 | holding | — | — | — | 117,028 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- F2The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.